As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of ...

Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...

Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate ...

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025 ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

Researchers at the Nanoscience Initiative, Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have made what they describe as a breakthrough in the fight against viral diseases, ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based ...

Headshot of Sumit Chanda standing outside Scripps Research Institute. Sumit Chanda has dedicated his career to antiviral drug research. Credit: Courtesy of the Chanda Lab The US National Institutes of ...

BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (COCP). (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and ...

We harness our revolutionary, structure-based drug discovery platform technology to engineer next-generation, broad-spectrum antivirals that precisely disrupt viral replication mechanisms. Unlike ...